{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T18:26:41Z","timestamp":1747852001227},"reference-count":29,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The \u201cgold standard\u201d assay for measuring serologic protection against\n            <jats:italic>Neisseria meningitidis<\/jats:italic>\n            group B (MenB) is the serum bactericidal antibody (SBA) assay. Of vital importance to the outcome of the SBA assay is the choice of the target strain(s), which is often chosen on the basis of phenotype or genotype. We therefore investigated the effect on the results produced by the SBA assay of using phenotypically indistinguishable but geographically distinct MenB isolates. Nine PorA P1.19,15 and 11 PorA P1.7-2,4 MenB isolates were incorporated into the SBA assay using human complement and were assayed against sera obtained either before or after outer membrane vesicle vaccination. Large differences in the results produced by the isolates in the SBA assay were demonstrated. These included differences as great as 5.8-fold in SBA geometric mean titers and in the proportions of subjects with SBA titers of \u22654. Ranges of as many as 9 SBA titers were achieved by individual sera across the panels of isolates. To determine the reasons for the differences observed, investigations into the expression of capsular polysaccharide, PorA, PorB, Opc, and lipooligosaccharide (LOS) and into LOS sialylation were completed. However, minor differences were found between strains, indicating similar expression and no antigen masking. These results have implications for the choice of MenB target strains for inclusion in future studies of MenB vaccines and highlight the requirement for standardization of target strains between laboratories.\n          <\/jats:p>","DOI":"10.1128\/cvi.00195-07","type":"journal-article","created":{"date-parts":[[2007,9,20]],"date-time":"2007-09-20T00:48:52Z","timestamp":1190249332000},"page":"1451-1457","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["Comparison of Phenotypically Indistinguishable but Geographically Distinct\n            <i>Neisseria meningitidis<\/i>\n            Group B Isolates in a Serum Bactericidal Antibody Assay"],"prefix":"10.1128","volume":"14","author":[{"given":"Jamie","family":"Findlow","sequence":"first","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, 2nd Floor, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester, M13 9WZ"},{"name":"Health Protection Agency, Centre for Infections, Colindale, London, NW9 5EQ, United Kingdom"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Finlay Institute, Ave 27N. 19085, La Lisa A P 160017, Cod 11600, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Holland","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, 2nd Floor, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester, M13 9WZ"},{"name":"Health Protection Agency, Centre for Infections, Colindale, London, NW9 5EQ, United Kingdom"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Finlay Institute, Ave 27N. 19085, La Lisa A P 160017, Cod 11600, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Andrews","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, 2nd Floor, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester, M13 9WZ"},{"name":"Health Protection Agency, Centre for Infections, Colindale, London, NW9 5EQ, United Kingdom"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Finlay Institute, Ave 27N. 19085, La Lisa A P 160017, Cod 11600, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Weynants","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, 2nd Floor, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester, M13 9WZ"},{"name":"Health Protection Agency, Centre for Infections, Colindale, London, NW9 5EQ, United Kingdom"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Finlay Institute, Ave 27N. 19085, La Lisa A P 160017, Cod 11600, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franklin","family":"Sotolongo","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, 2nd Floor, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester, M13 9WZ"},{"name":"Health Protection Agency, Centre for Infections, Colindale, London, NW9 5EQ, United Kingdom"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Finlay Institute, Ave 27N. 19085, La Lisa A P 160017, Cod 11600, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Balmer","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, 2nd Floor, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester, M13 9WZ"},{"name":"Health Protection Agency, Centre for Infections, Colindale, London, NW9 5EQ, United Kingdom"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Finlay Institute, Ave 27N. 19085, La Lisa A P 160017, Cod 11600, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Poolman","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, 2nd Floor, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester, M13 9WZ"},{"name":"Health Protection Agency, Centre for Infections, Colindale, London, NW9 5EQ, United Kingdom"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Finlay Institute, Ave 27N. 19085, La Lisa A P 160017, Cod 11600, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, P.O. Box 209, 2nd Floor, Clinical Sciences Building II, Manchester Royal Infirmary, Manchester, M13 9WZ"},{"name":"Health Protection Agency, Centre for Infections, Colindale, London, NW9 5EQ, United Kingdom"},{"name":"GlaxoSmithKline Biologicals, Rixensart, Belgium"},{"name":"Finlay Institute, Ave 27N. 19085, La Lisa A P 160017, Cod 11600, Havana, Cuba"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Opsonophagocytic activity and IgG responses against live meningococci after vaccination with a combination of two serogroup B OMV vaccines 2005"},{"key":"e_1_3_2_3_2","first-page":"970","volume":"12","year":"2005","unstructured":"Borrow, R., I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J. Findlow, E. A. H\u00f8iby, E. Rosenqvist, P. Balmer, and D. Martin. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol.12:970-976.","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","volume":"24","year":"2006","unstructured":"Borrow, R., G. M. Carlone, N. Rosenstein, M. Blake, I. Feavers, D. Martin, W. Zollinger, J. Robbins, I. S. Aaberge, D. M. Granoff, E. Miller, B. Plikaytis, L. van Alphen, J. Poolman, R. Rappuoli, L. Danzig, J. Hackell, B. Danve, M. Caulfield, S. Lambert, and D. Stephens. 2006. Neisseria meningitidis group B correlates of protection and assay standardization\u2014international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine24:5093-5107.","journal-title":"Vaccine"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0264-410X(94)00037-N","volume":"13","year":"1995","unstructured":"Boslego, J., J. Garcia, C. Cruz, W. Zollinger, B. Brandt, S. Ruiz, M. Martinez, J. Arthur, P. Underwood, W. Silva, E. Moran, W. Hankins, J. Gilly, P. Mays, and The Chilean National Committee for Meningococcal Disease. 1995. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine13:821-829.","journal-title":"Vaccine"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00230-06"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.vaccine.2004.11.029","volume":"23","year":"2005","unstructured":"Findlow, J., A. Lowe, S. Deane, P. Balmer, G. van den Dobbelsteen, M. Dawson, N. Andrews, and R. Borrow. 2005. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children. Vaccine23:2623-2627.","journal-title":"Vaccine"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00466-06"},{"key":"e_1_3_2_9_2","first-page":"355","year":"1983","unstructured":"Finne, J., M. Leinonen, and P. H. M\u00e4kel\u00e4. 1983. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancetii:355-357.","journal-title":"Lancet"},{"key":"e_1_3_2_10_2","first-page":"67","volume":"14","year":"1991","unstructured":"Fredriksen, J. H., E. Rosenqvist, E. Wedege, K. Bryn, G. Bjune, L. O. Froholm, A. K. Lindbak, B. Mogster, E. Namork, U. Rye, G. Stabbertorp, R. Winsnes, A. Aase, and O. Closs. 1991. Production, characterization and control of MenB-vaccine \u201cFolkehelsa\u201d: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann.14:67-80.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","volume":"103","year":"2006","unstructured":"Giuliani, M. M., J. Adu-Bobie, M. Comanducci, B. Arico, S. Savino, L. Santini, B. Brunelli, S. Bambini, A. Biolchi, B. Capecchi, E. Cartocci, L. Ciucchi, F. Di Marcello, F. Ferlicca, B. Galli, E. Luzzi, V. Masignani, D. Serruto, D. Veggi, M. Contorni, M. Morandi, A. Bartalesi, V. Cinotti, D. Mannucci, F. Titta, E. Ovidi, J. A. Welsch, D. Granoff, R. Rappuoli, and M. Pizza. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. USA103:10834-10839.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","volume":"55","year":"2006","unstructured":"Gray, S. J., C. L. Trotter, M. E. Ramsay, M. Guiver, A. J. Fox, R. Borrow, R. H. Mallard, and E. B. Kaczmarski. 2006. Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/4: contribution and experiences of the Meningococcal Reference Unit. J. Med. Microbiol.55:887-896.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0264-410X(02)00591-1","volume":"21","year":"2003","unstructured":"Holst, J., B. Feiring, J. E. Fuglesang, E. A. H\u00f8iby, H. Nokleby, I. S. Aaberge, and E. Rosenqvist. 2003. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine21:734-737.","journal-title":"Vaccine"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.13.4.486-491.2006"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/cdli.4.2.156-167.1997"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1574-695X.2000.tb01493.x","volume":"28","year":"2000","unstructured":"Milagres, L. G., M. C. Gorla, M. C. Rebelo, and D. E. Barroso. 2000. Bactericidal antibody responses to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunisation with an outer membrane protein vaccine. FEMS Immunol. Med. Microbiol.28:319-327.","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.10.4755-4761.1998"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.12.5290-5295.1994"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","volume":"23","year":"2005","unstructured":"Oster, P., D. Lennon, J. O'Hallahan, K. Mulholland, S. Reid, and D. Martin. 2005. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine23:2191-2196.","journal-title":"Vaccine"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.63.12.4642-4652.1995"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1099\/00222615-41-4-236","volume":"41","year":"1994","unstructured":"Scholten, R. J., B. Kuipers, H. A. Valkenburg, J. Dankert, W. D. Zollinger, and J. T. Poolman. 1994. Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies. J. Med. Microbiol.41:236-243.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_2_22_2","first-page":"195","volume":"14","year":"1991","unstructured":"Sierra, G. V. C., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14:195-210.","journal-title":"NIPH Ann."},{"key":"e_1_3_2_23_2","first-page":"1520","volume":"281","year":"1999","unstructured":"Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. H\u00f8iby, J. Holst, H. Nokleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomised controlled trial in Chile. JAMA281:1520-1527.","journal-title":"JAMA"},{"key":"e_1_3_2_24_2","unstructured":"Characterisation of serogroup C strains of Neisseria meningitidis that are resistant to killing by sera from individuals immunised with the serogroup C conjugate vaccine 2005"},{"key":"e_1_3_2_25_2","unstructured":"From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine 2004"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.60.8.3156-3161.1992"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.71.4.1650-1655.2003"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.7.3223-3231.1998"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","volume":"126","year":"1972","unstructured":"Wyle, F. A., M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal. 1972. Immunological response of man to group B meningococcal polysaccharide antigens. J. Infect. Dis.126:514-522.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/0161-5890(91)90010-H","volume":"28","year":"1991","unstructured":"Yamasaki, R., W. Nasholds, H. Schneider, and M. A. Apicella. 1991. Epitope expression and partial structural characterization of F62 lipooligosaccharide (LOS) of Neisseria gonorrhoeae: IgM monoclonal antibodies (3F11 and 1-1-M) recognize nonreducing termini of the LOS components. Mol. Immunol.28:1233-1242.","journal-title":"Mol. Immunol."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00195-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00195-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:37:39Z","timestamp":1627591059000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00195-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1128\/CVI.00195-07"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00195-07","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11]]},"assertion":[{"value":"2007-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-09-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}